Full-Time

DevOps Engineer

Cloud Infrastructure & Scientific Computing

Updated on 8/21/2026

Cartography Biosciences

Cartography Biosciences

51-200 employees

Develops precision immunotherapies targeting antigens

Compensation Overview

$130k - $145k/yr

Remote in USA

Remote

Fully remote across the Americas, including the United States, Canada, Mexico, Central America, and South America. Must maintain meaningful synchronous overlap with US Pacific Time.

Category
DevOps & Infrastructure (2)
,
Required Skills
Graphics Processing Unit (GPU)
Python
Airflow
Incident Response
High Performance Computing (HPC)
Git
Machine Learning
Docker
SOC 2
AWS
Cryptography
Terraform
Observability
DevOps
Linux/Unix
HIPAA
Google Cloud Platform

Get referred to Cartography Biosciences

See people who can refer or advise you

Requirements
  • At least 4 years of hands-on DevOps, site reliability engineering, or cloud infrastructure experience.
  • Strong production experience with Google Cloud Platform, including Google Compute Engine, Google Kubernetes Engine, Google Cloud Storage, Cloud Run, Identity and Access Management, Cloud Logging, and Batch, plus working knowledge of Amazon Web Services, including Amazon Elastic Compute Cloud, Amazon Simple Storage Service, Identity and Access Management, and Lambda.
  • Deep proficiency with Terraform, GitHub Actions or equivalent continuous integration and continuous delivery systems, and Docker.
  • Proficiency in Python for scripting, automation, and data handling, with comfort using Unix or Linux terminal environments.
  • Practical experience implementing data security controls, including encryption, access policies, secrets management, and audit trails.
  • Demonstrated ability to maintain internal-facing applications and services with high uptime expectations.
  • Excellent written and verbal communication in English, with the ability to document systems clearly for engineers and scientists.
  • Availability for working hours that include meaningful synchronous overlap with US Pacific Time.
Responsibilities
  • Architect, deploy, and maintain cloud infrastructure across Google Cloud Platform and Amazon Web Services, focusing on cost efficiency, reproducibility, and security across compute, storage, networking, and identity.
  • Manage infrastructure as code using Terraform, with full version control through GitHub and continuous integration and continuous delivery pipelines supporting scientific computing and internal application deployment.
  • Support and extend scientific computing infrastructure, including Cromwell, Google Batch, Cloud Run, Cloud Storage, and GPU-accelerated environments for protein design, structural prediction, and machine learning workloads.
  • Maintain uptime, observability, and incident response for internal applications, including Slack integrations, web dashboards, and data ingestion services connecting laboratory and computational workflows.
  • Implement and uphold data security practices for a biotech environment, including Identity and Access Management, secrets management, audit logging, network segmentation, and compliance-adjacent controls.
  • Collaborate with computational biologists and software engineers to operationalize new tools and pipelines, translating prototype workflows into reliable production systems.
  • Triage and resolve infrastructure issues across the stack, documenting resolutions and conducting post-mortems to improve the system over time.
  • Articulate technical decisions and trade-offs to engineering and scientific teams.
Desired Qualifications
  • Fluency with artificial-intelligence-augmented development workflows, including practical use of Claude Code, Cursor, or GitHub Copilot in infrastructure and scripting work.
  • Experience supporting scientific or research computing environments, including genomics, single-cell, structural biology, machine learning, or high-performance computing.
  • Familiarity with workflow orchestration systems such as Cromwell, Nextflow, Workflow Description Language, or Airflow.
  • Experience with GPU infrastructure and scheduling machine learning or protein design workloads.
  • Background in life sciences infrastructure, including familiarity with Benchling, electronic laboratory notebook integrations, or scientific data management systems.
  • Prior experience at an early-stage biotech, scientific software company, or research-driven startup.
  • Familiarity with SOC 2, HIPAA-adjacent, or other regulated-environment security frameworks.
Cartography Biosciences

Cartography Biosciences

View

Cartography Biosciences develops precision cancer immunotherapies. It identifies therapeutic targets by analyzing cancers through antigen expression instead of histology or genetic mutations, enabling therapies that specifically engage tumor cells while aiming to minimize harm to healthy tissue. The company designs and commercializes targeted immunotherapies and seeks druggable targets in cancers that are currently untreatable, striving for treatments that are as safe as they are effective and broadly applicable across tumor cells within a patient. In short, its goal is to deliver precise, safe, and potent cancer treatments by pairing a unique target-identification approach with immunotherapy platforms, and to bring these therapies to healthcare providers and patients through commercialization.

Company Size

51-200

Company Stage

Series B

Total Funding

$124M

Headquarters

Foster City, California

Founded

2020

Get referred to Cartography Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 2026 Samsung Ventures investment added capital and strategic life-sciences backing.
  • January 2026 Pfizer deal brings up to $65 million upfront and milestone payments.
  • Phase 1 enrollment for CBI-1214 started in 2026, creating near-term clinical catalysts.

What critics are saying

  • CBI-1214 faces first-in-human readouts in 2026; safety failure kills the platform.
  • Pfizer controls collaboration programs after opt-ins, limiting Cartography's downstream economics.
  • Any off-tumor toxicity from LY6G6D or future targets would undermine Cartography's thesis.

What makes Cartography Biosciences unique

  • ATLAS and SUMMIT map single-cell antigens across tumors and healthy tissues.
  • CBI-1214 targets LY6G6D in MSS and MSI-L colorectal cancer, a high-unmet-need niche.
  • Pfizer and Gilead validated Cartography's target-discovery platform with active collaborations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
Business Wire
May 8th, 2026
Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline

Cartography Biosciences and Samsung Ventures today announced a strategic investment to support the advancement of Cartography’s differentiated oncology pipel...

AllSci
May 7th, 2026
Cartography Biosciences secures strategic investment from Samsung Ventures for oncology pipeline.

Cartography Biosciences secures strategic investment from Samsung Ventures for oncology pipeline. May 7, 2026 South San Francisco-based Cartography Biosciences has received a strategic equity investment from Samsung Ventures to support the advancement of its oncology pipeline and proprietary antigen discovery platforms. The investment amount was not disclosed. The capital was deployed through the Samsung Life Science Fund, which was established by Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C\&T, and is managed by Samsung Ventures. The fund directs capital toward biopharmaceutical companies working across biologics, gene editing, and AI-enabled therapeutics. No additional participating investors were named. Cartography said the partnership is intended to leverage Samsung's life sciences network alongside the company's own antigen discovery and drug development capabilities. The Samsung investment follows a USD 67 million Series B closed in October 2025, led by Pfizer Ventures, with participation from LG Corp, Amgen Ventures, Finchley Healthcare Ventures, Global BioAccess Fund, and Lotte Holdings CVC. The company's first financing - a combined seed and Series A totaling USD 57 million - was raised in July 2022 and led by 8VC. Cartography's pipeline centers on antibody-based therapies designed to engage the immune system against solid tumors. Its lead candidate, CBI-1214, is a T-cell engager targeting LY6G6D in microsatellite stable and microsatellite instability-low colorectal cancer - a patient population with limited options under current immunotherapy approaches. CBI-1214 entered the clinic in early 2026 and is currently enrolling patients in a Phase I study. The company's broader pipeline, while not fully disclosed in public materials, is built around the same antigen discovery logic and is focused on oncology indications where tumor selectivity represents a clinical differentiator. The platforms underpinning Cartography's pipeline - ATLAS and SUMMIT - are designed to address a persistent challenge in cancer immunotherapy: on-target, off-tumor toxicity arising from the expression of therapeutic targets on healthy tissue. ATLAS generates single-cell resolution maps of antigen expression across both normal human tissues and patient tumors, drawing on a dataset the company describes as spanning hundreds of thousands of cell states. The scientific rationale for this approach is that bulk sequencing methods average gene expression across mixed cell populations and can obscure rare but clinically relevant expression in normal tissues - a resolution gap that single-cell profiling is designed to close. The SUMMIT platform extends this logic by identifying combinations of antigens whose co-expression is restricted to tumor cells, even when individual antigens within the combination are also found on healthy tissue. This AND-gate combinatorial strategy is intended to expand the pool of actionable targets beyond what single-antigen approaches allow. In January 2026, Cartography announced a collaboration with Pfizer under which it will apply ATLAS and SUMMIT to identify tumor-selective antigens in an undisclosed indication. The deal includes up to USD 65 million in upfront and near-term milestone payments, with total potential value reaching USD 865 million. Pfizer Ventures had joined the Series B just months prior, with Michael Baran, Partner at Pfizer Ventures, joining Cartography's board as part of that round. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Business Wire
Feb 24th, 2026
Cartography Biosciences doses first patient with CBI-1214 T-cell engager in colorectal cancer trial

Cartography Biosciences has dosed the first patient in a Phase 1 trial of CBI-1214, a T-cell engager targeting LY6G6D for microsatellite stable or microsatellite instability-low colorectal cancer. The South San Francisco-based company developed the therapy using its ATLAS and SUMMIT platforms, which identify tumour-specific targets to reduce off-tumour toxicity. MSS/MSI-L tumours represent approximately 95% of colorectal cancer cases and are largely unresponsive to current immunotherapies. The open-label study will evaluate safety, tolerability, pharmacokinetics and preliminary anti-tumour activity in adults with advanced or metastatic disease. Colorectal cancer is the second leading cause of cancer-related mortality worldwide, with more than 1.9 million new cases diagnosed annually. Five-year survival rates for metastatic cases remain below 15%.

GenomeWeb
Jan 6th, 2026
Cartography Bio, Pfizer Collaborate on Tumor Antigen Discovery Effort

Cartography bio, Pfizer collaborate on tumor antigen discovery effort. NEW YORK - Cartography Biosciences said on Tuesday it will collaborate with Pfizer to use its drug discovery platforms to identify tumor-selective antigens for an undisclosed cancer indication. To read the full story...

Business Wire
Oct 7th, 2025
Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic

Cartography Biosciences, Inc., an oncology company advancing an innovative pipeline of T-cell engaging bispecific and multi-specific antibody therapeutics th...